Italia markets closed

Oryzon Genomics S.A. (0RDB.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
2,2400+0,0400 (+1,82%)
Alla chiusura: 05:28PM BST
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients

    In combination with gilteritinibPrimary objectives: to assess safety, tolerability and RP2DSecondary objectives: to assess efficacy MADRID, Spain and BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in its Phase Ib trial of iadademstat in combination with gilteritinib

  • GlobeNewswire

    ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders

    A highly selective HDAC-6 inhibitorRescues motor-neuronal deficiencies in a Charcot-Marie-Tooth modelTo start IND enabling studies MADRID, Spain and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the nomination of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor, as clinical development c

  • GlobeNewswire

    ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology

    Monday, February 27th at 10am ETMADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will host a virtual panel discussion, featuring Dr. Dyanna Phillips Domilici (Adams Clinical & Copley Clinical), Dr. med. Peter Hahn (Investigator & Neurology Specialist, emovis), and Dr. Olga Salame